NCT04244253View on ClinicalTrials.gov

A Phase 2 Trial of OPC-64005 for Major Depressive Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

273

Participants

Timeline

Start Date

March 3, 2020

Primary Completion Date

February 8, 2022

Study Completion Date

February 25, 2022

Conditions
Major Depressive Disorder
Interventions
DRUG

OPC-64005 20 mg , Once-daily

Active, High Dose

DRUG

OPC-64005 10 mg , Once-daily

Active, Low Dose

DRUG

Placebo, Once-daily

Placebo

Trial Locations (1)

Unknown

Medical Corporation Jisenkai Himorogi Psychiatric Institute, Tokyo

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY